REUTERS: An experimental Amgen Inc drug that targets a specific genetic mutation significantly reduced tumor size in half of evaluated patients with advanced lung cancer in a small, early-stage trial, researchers said on Monday, sending the U.S. biotechnology company's share up nearly 6 percent.
No serious side effects were reported in data presented in Chicago at the American Society of Clinical Oncology meeting. "In principle, this drug has the potential to be effective in any patient with the KRAS mutation," Elliott Levy, Amgen's head of global development, said in an interview.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Seattle Genetics, Astellas drug rapidly shrinks tumors in bladder cancer studyAn experimental drug developed by Seattle Genetics Inc and Astellas Pharma Inc led to significant, rapid tumor shrinkage in patients with advanced ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Newron delays schizophrenia drug trial after FDA raises concernsZURICH: Swiss-listed drugmaker Newron must delay a trial of its prospective schizophrenia medicine evenamide after the U.S. Food and Drug ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Johnson & Johnson told by jury to pay US$300 million more in talc-cancer case[NEW YORK] Johnson & Johnson was ordered by a jury to pay US$300 million in punitive damages to a woman who blamed her rare asbestos-related cancer on decades of daily use of the company's talc-based products. Read more at The Business Times.
Source: BusinessTimes - 🏆 15. / 51 Read more »
Race disparity in US prostate cancer deaths disappears with equal care(Reuters Health) - Black men are more likely to die of prostate cancer than white men in the U.S., but a new study suggests this racial disparity ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »